Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Fetal, Abdominal, Small Organ (Breast, Thyroid, Testes), Cardiac, Transrectal, Transvaginal, Peripheral Vascular, Musculo-skeletal Conventional.

Device Description

The Perception's GPS-6TBMD Ultrasound System is a PC (computer) based and controlled real time. two dimensional, mechanical sector and electronic array diagnostic ultrasound and pulsed Doppler imaging system which produces diagnostic ultrasonic images and blood flow spectral analysis through user friendly operation. User interface is via an alphanumeric keypad, trackball and Icon-driven graphical interface. The Perception Inc. GPS-6TBMD Diagnostic Ultrasound System may be operated in M /B /D modes of inspection. The Perception GPS-6TBMD Diagnostic Ultrasound System supports M. B. M&B, Dual B, Quad B, D and D/B, display modes. All probes currently intended for use with the Perception GPS-6TBMD Diagnostic Ultrasound System are either mechanical sector devices or electronic linear and curve array, and make use of a fluid filled design.

AI/ML Overview

This appears to be a 510(k) summary for the Perception Inc. GPS-6TBMD Diagnostic Ultrasound System, dated September 29, 1998. It details the device, its intended uses, and its substantial equivalence to predicate devices.

However, the provided document explicitly states:

"8. Discussion of Clinical Test Performed: Not Applicable" (Page 3)

This means that no clinical study was performed to prove the device meets acceptance criteria in a clinical setting. Instead, the submission focuses on non-clinical tests to demonstrate substantial equivalence to legally marketed predicate devices.

Therefore, I cannot provide information on acceptance criteria related to clinical performance, how ground truth was established, sample sizes, or expert qualifications for a clinical study, as no such study is documented in this 510(k) summary.

Here's what I can extract regarding the non-clinical acceptance criteria and tests:

Acceptance Criteria and Device Performance (Non-Clinical)

Acceptance Criteria Category	Specific Criteria/Standard	Reported Device Performance
Acoustic Output	Standards: NEMA 1992, Acoustic output measurement standard for diagnostic ultrasound equipment, NEMA Standard UD-21992. FDA Center for Devices and Radiological Health 1985 510(k) Guide for Measuring and Reporting and Acoustic Output of Diagnostic Ultrasound Medical Devices (Revised, 1989, 1990, 1991,1993, 1994, and 1995). Specific Assessments: Maximum Acoustic Output Information, Estimated In-Situ Intensity, FDA In-Situ Intensity Limits, Acoustic Output Information for each system/transducer/mode combination.	Acoustic output for each system/transducer/mode/application combination was measured and calculated per the above documents. The testing conducted "revealed satisfactory testing results and compliance to applicable standards." No design characteristics were found that violated the requirements of the September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers, FDA, Center for Devices and Radiological Health," or resulted in any safety hazards. The contract testing laboratory concluded that the device met all relevant requirements of the aforementioned guidance testing requirements.
Electrical Safety	UL-544, Third Edition	Satisfactory testing results and compliance to applicable standards.
Electromagnetic Compatibility (EMC)	Emissions: - Radiated and Conducted Emissions per CISPR 11 - Magnetic Field Emissions per MIL-STD-482D, method RE101 Immunity: - Electrostatic Discharge Immunity per IEC 801-2 - Radiated Field Immunity (3 V/m, 26 MHz to 1 Ghz, 100% Square wave Modulation) - Steady State Voltage Fluctuations - Line Voltage Dropouts - Slow Line Voltage Sags and Surges - Fast Transients Bursts per IEC 801-4 - Fast Line Voltage Surges - Conducted Energy Immunity per MIL-STD-462D, Method CS114 - Magnetic Field Immunity per MIL-STD-482D, Method RS 101 - Quasi-Static Electric Field Immunity	Satisfactory testing results and compliance to applicable standards. No design characteristics were found that violated the requirements of the September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers, FDA, Center for Devices and Radiological Health," or resulted in any safety hazards. The contract testing laboratory concluded that the device met all relevant requirements of the aforementioned guidance testing requirements.
Biocompatibility	(Implicitly tested as stated in the conclusion.)	"Biocompatibility testing revealed no new questions of safety or effectiveness." (Specific standards or detailed results are not provided in this summary.)
Substantial Equivalence	The device should have the same intended use, method of operation, materials, and design, or comparable without raising new questions of safety or effectiveness, as legally marketed predicate devices.	The Perception Inc. GPS-6TBMD Diagnostic Ultrasound System has the same intended use as a combination of all cited predicates. All non-clinical testing and biocompatibility testing revealed no new questions of safety or effectiveness. When compared to the predicate devices, the device "does not incorporated any significant changes in intended use, method of operations, material or design that could affect safety or effectiveness."

Study Details (Non-Clinical Testing)

Since no clinical study was performed, the following points relate to the non-clinical testing described:

Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective):
- This information is not applicable for non-clinical testing of a diagnostic ultrasound system's technical specifications and safety. The "test set" in this context refers to the device itself and its components. The provenance would be the manufacturing site and testing laboratories.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not applicable in the sense of clinical ground truth. The "experts" involved would be the contract testing laboratory personnel who conducted the engineering and safety tests, qualified to perform tests against the listed standards (e.g., UL, CISPR, IEC, MIL-STD, NEMA). Their specific number or qualifications are not detailed in this summary.
Adjudication method (e.g., 2+1, 3+1, none) for the test set:
- Not applicable for non-clinical engineering and safety testing. Compliance is determined by whether the device's measured performance meets the specified thresholds or requirements of the cited standards.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No. This is a diagnostic ultrasound system from 1998, which is a hardware device. There is no mention of AI or image analysis software that would involve human readers or MRMC studies.
If a standalone (i.e., algorithm only without human-in-the loop performance) was done:
- No. Not applicable for this type of device.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- For the non-clinical tests, the "ground truth" refers to the established technical standards and regulatory limits (e.g., maximum acoustic output levels, acceptable EMI/EMC performance thresholds).
The sample size for the training set:
- Not applicable, as there is no algorithmic component requiring a training set for machine learning.
How the ground truth for the training set was established:
- Not applicable.

Summary

{0}------------------------------------------------

SEP 2 9 1998

L 981834
EXHIBIT #B
8 Pages

510(k) SUMMARY

This summary of 510(k) Safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: K981 834 .

1. Submitter's Identification :

Perception Inc. 9344 N.W. 13th Street, Suite 200 Miami, Florida 33172 Contact Person : Mr. Jorge Millan

Date Summary Prepared: April 17, 1998

2. Name of the Device :

Perception Inc. GPS-6TBMD Diagnostic Ultrasound System

3. Predicate Device Information :

1. Aloka Co. SSD-1700 K963616 Model

2. Diasonics Ultrasound

Models	SynergyCFM800EchoPac	K935024 K924079 K962662
--------	------------------------------	-------------------------------

3. Perception Inc.

Model	GPS-TUV	K#972973.
Model	GPS-XYZ	K#972192

1. Pie Medical Ultrasound Model Scanner #1150 K#900469

5. International Ultrasound Co. HRI 2000 K#961229 Model

{1}------------------------------------------------

4. Device Description :

General Description

The following intended uses are identified for the transducer applications: General Radiology, Urology, Abdominal, Cardiac, Trans-vaginal, Trans-rectal, Vascular, Small Organs, Breast, Thyroid, Fetal Imaging and Musculo-Skeletal (conventional) with the use of ultrasonic probes from 3.0-12.5 MHz. There are no transcranial applications for this device.

User interface is via an alphanumeric keypad, trackball and Icon-driven graphical interface. The Perception Inc. GPS-6TBMD Diagnostic Ultrasound System may be operated in M /B /D modes of inspection. The Perception GPS-6TBMD Diagnostic Ultrasound System supports M. B. M&B, Dual B, Quad B, D and D/B, display modes.

All probes currently intended for use with the Perception GPS-6TBMD Diagnostic Ultrasound System are either mechanical sector devices or electronic linear and curve array, and make use of a fluid filled design. Transducer parameters are summarized in the following table:

App/Prob/Freq(MHz)	GP-3.02.8	CA-3.53.5	EV-6.56.5	ER-6.56.5	LA-7.56.5	PV-12.512.5
Abdominal	M/B/PWD	B/PWD
Cardiac	M/B/PWD	B/PWD
Vascular					M/B/PWD	M/B
Trans-rect				B
Trans-vag			M/B
Small OrganBreast, Thyroid,Testes, Musculo-skeleta	M/B/PWD	B/PWD			B	B
Fetal	M/B	B	M/B

{2}------------------------------------------------

5. Intended Use:

See Attachment.

6. Comparison to Predicate Devices:

We believe the Perception Inc. GPS-6TBMD Diagnostic Ultrasound System to be substantially equivalent to ultrasound devices currently in commercial distribution in the U.S. A table of comparison outlining similarities and differences between the Perception Inc. GPS-6TBMD Diagnostic Ultrasound System and predicate devices is attached to this summary.

7. Discussion on Non-Clinical Test Performed for Determination of Substantial Equivalence are as Follows:

This 510(k) submission is intended as a Track 1 type submission. Acoustic Output Reporting was prepared utilizing the following documents.

NEMA 1992, Acoustic output measurement standard for diagnostic . ultrasound equipment, NEMA Standard UD-21992.
FDA Center for Devices and Radiological Health 1985 510(k) Guide for . Measuring and Reporting and Acoustic Output of Diagnostic Ultrasound Medical Devices, December 1985, Revised, 1989, 1990, 1991,1993, 1994, and 1995.

Acoustic output of each system/transducer/mode/application combination was measured and calculated per the above documents. The following testing was conducted which revealed satisfactory testing results and compliance to applicable standards.

Maximum Acoustic Output Information .
Estimated In-Situ Intensity .
FDA In-Situ Intensity Limits ●
Acoustic Output Information for each system/transducer/mode . combination

A contract-testing laboratory conducted the following testing:

UL-544, Third Edition ●
Radiated and Conducted Emissions per CISPR 11 ●
Magnetic Field Emissions per MIL-STD-482D, method RE101 .
Electrostatic Discharge Immunity per IEC 801-2 .

{3}------------------------------------------------

Radiated Field Immunity (3 V/m,26 MHz to 1 Ghz,100% Square wave Modulation)
Steady State Voltage Fluctuations ●
Line Voltage Dropouts ●
Slow Line Voltage Sags and Surges .
Fast Transients Bursts per IEC 801-4 .
Fast Line Voltage Surges ●
Conducted Energy Immunity per MIL-STD-462D, Method CS114 .
Magnetic Field Immunity per MIL-STD-482D,Method RS 101 .
Quasi-Static Electric Field Immunity .

None of the testing demonstrated any design characteristics that violated the requirements of the September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers, FDA, Center for Devices and Radiological Health" or resulted in any safety hazards. It was the contract testing Laboratory's conclusions that the device tested met all relevant requirements of the aforementioned guidance testing requirements.

8. Discussion of Clinical Test Performed:

Not Applicable

9. Conclusions:

The Perception Inc. GPS-6TBMD Diagnostic Ultrasound System has the same intended use as a combination of all cited predicates. All non-clinical testing and biocompatibility testing revealed no new questions of safety or effectiveness. This, when compared to the predicate devices, the Perception Inc. GPS-6TBMD Diagnostic Ultrasound System does not incorporated any significant changes in intended use, method of operations, material or design that could affect safety or effectiveness.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States of America. The seal features a circular design with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an emblem of an eagle with its wings spread, symbolizing the department's mission to protect the health of all Americans and provide essential human services.

SEP 2 9 10

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Jorge Millan Official Correspondent Perception, Inc. 9344 N.W. 13th Street Suite 200 Miami, FL 33172

K981834 Re : GPS-6TMD Diagnostic Ultrasound System Regulatory Class: II/21 CFR 892.1550 Product Code: 90 IYN Dated: September 10, 1998 September 11, 1998 Received:

Dear Mr. Millan:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the GPS-6TMD Diagnostic Ultrasound System, as described in your premarket notification:

Transducer Model Number

GP-3.0 MHz Mechanical Sector CA-3.5 MHz Curved Array EV-6.5 MHz Curved Array ER-6.5 MHz Mechanical Sector LA-7.5 MHz Linear Array PV-12.5 MHz Mechanical Sector

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic QS inspections, the FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification does not affect any obligation you may have under sections 531 and 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{5}------------------------------------------------

Page 2 - Jorge Millan

Please be advised that the determination above is based on the fact that no medical devices have been demonstrated to be safe and effective for in vitro fertilization or percutaneous umbilical blood sampling, nor have any devices been marketed for these uses in interstate commerce prior to May 28, 1976, or reclassified into class I (General Controls) or class II (Special Controls). FDA considers devices specifically intended for in vitro fertilization and percutaneous umbilical blood sampling to be investigational, and subject to the provision of the investigational device exemptions (IDE) regulations, 21 CFR, Part 812. Therefore, your product labeling must be consistent with FDA's position on this use.

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its tollfree number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

If you have any questions regarding the content of this letter, please contact Rodrigo C. Perez at (301) 594-1212.

Sincerely yours,

Jind li. Sejim
Lillian Yin, PhD

illian Yin, PH.D. Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal		X	X						M+ref B
Abdominal		X	X	X					M+ref BPWD + ref B
Intraoperative(specify
IntraoperativeNeurological
Pediatric
Small Organ (specify)		X	X	X					M+ref BPWD + ref B
Neonathal Cephalic
Adult Cephalic
Cardiac		X	X	X					M+ref BPWD + ref B
Transesophageal
Transrectal		X
Transvaginal		X	X						M+ref B
Transurethral
Intravascular
Peripheral Vascular		X	X	X					M+ref BPWD + ref B
Laparoscopic
Musculo-skeletalConventional		X	X	X					M+ref BPWD + ref B
Musculo-skeletalSuperficial
Other (specify)

GPS-6TBMD - ULTRASOUND SYSTEM

N= new indication; P= previously cleared by FDA; E= Added under Appendix E

Additional Comments: Small Organs: Breast, Thyroid, Testes.

STO(k) Number

Jain Se

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,

and Radiological Devices

Prescription Use _ (Per 21 CFR 801.109) سسسسسسسس

{7}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal		X	X						M+ ref B
Abdominal		X	X	X					M+ ref BPWD + ref B
Intraoperative(specify)
IntraoperativeNeurologicalPediatric
Small Organ (specify)		X	X	X					M+ ref BPWD + ref B
Neonathal Cephalic
Adult Cephalic
Cardiac		X	X	X					M+ ref BPWD + ref B
Transesophageal
Transrectal
Transvaginal
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional		X	X	X					M+ ref BPWD + ref B
Musculo-skeletalSuperficial
Other (specify)

GP-3.0 MHz Mechanical Sector-Transducer

N= new indication; P= previously cleared by FDA; E= Added under Appendix E

Additional Comments: Small Organs: Breast, Thyroid, Testes.

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
Prescription Use
(Per 21 CFR 801.109)
510(k) Number. K981834

{8}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal		×
Abdominal		×		×					PWD+ ref B
Intraoperative(specify)
IntraoperativeNeurologicalPediatric
Small Organ (specify)		×		×					PWD+ ref B
Neonathal Cephalic
Adult Cephalic
Cardiac		×	×	×					M+ ref BPWD+ ref B
Transesophageal
Transrectal
Transvaginal
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional		×		×					PWD+ ref B
Musculo-skeletalSuperficial
Other (specify)

CA-3.5 MHz Curve Array-Transducer

N= new indication; P= previously cleared by FDA; E= Added under Appendix E

Additional Comments: Small Organs: Breast, Thyroid, Testes.

Prescription Use
(Per 21 CFR 801.109) ✓

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K981834

{9}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal
ntraoperative(specify
IntraoperativeNeurological
Pediatric
Small Organ (specify)
Neonathal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal		X
Transvaginal
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletalSuperficial
Other (specify)

ER-6.5 MHz Mechanical-Transducer

Additional Comments: NONE

Simit U. Segun
(Division Sign-Off)

Division of Reproductive, Abdominal, ENT, and Radiological Deyi

510(k) Number ـ

ﺴﺎ

{10}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal		X	X						M+ ref B
Abdominal
Intraoperative(specify
IntraoperativeNeurological
Pediatric
Small Organ (specify)
Neonathal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal
Transvaginal		X	X						M+ ref B
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletalSuperficial
Other (specify)

EV-6.5 MHz Curve Array-Transducer

Additional Comments: NONE

Prescription Use
(Per 21 CFR 801.109) (Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K981834

{11}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal
Intraoperative(specify
IntraoperativeNeurological
Pediatric
Small Organ (specify)		X
Neonathal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal
Transvaginal
Transurethral
Intravascular
Peripheral Vascular	X	X	X						M+ ref BPWD+ ref B
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletalSuperficial
Other (specify)

LA-7.5 MHz Linear Array-Transducer

N= new indication; P= previously cleared by FDA; E= Added under Appendix E

Additional Comments: Small Organs: Breast, Thyroid, Testes.

and the comments of the comments of the comments of the comments of the comments of the comments of the contribution of the contribution of the contribution of the contributi

Prescription Use
(Per 21 CFR 801.109)

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K981834

{12}------------------------------------------------

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operations
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	Color VelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal
Intraoperative(specify)
IntraoperativeNeurological
Pediatric
Small Organ (specify)		X
Neonathal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal
Transvaginal
Transurethral
Intravascular
Peripheral Vascular	X	X	X						M + ref B
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletalSuperficial
Other (specify)

PV-12.5 MHz Mechanical Sector-Transducer

N= new indication; P= previously cleared by FDA; E= Added under Appendix E

Additional Comments: Small Organs: Breast, Thyroid, Testes.

Prescription Use
(Per 21 CFR 801.109)

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices.
510(k) Number. K981834

Regulation Number and Section

§ 892.1550 Ultrasonic pulsed doppler imaging system.

(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.